Interventional Oncology Market

Global Interventional Oncology Market Size (2023 to 2028)

The size of the global interventional oncology market is forecasted to be valued at USD 3.33 billion by 2028 from USD 2.34 billion in 2023, growing at a CAGR of 7.36% during the forecast period.

Interventional oncology procedures include cancer diagnosis and therapy using minimally invasive procedures performed under imaging guidance. Guidance is provided by equipment such as x-ray, ultrasound, computed tomography, or magnetic resonance imaging. Interventional oncologists can develop safe ways for doing minimally invasive tumor biopsies to obtain the genetic or proteomic data needed to precisely personalize the chemotherapeutic drugs that are likely to have the optimal therapy impact. Interventional oncology is used to treat cancers such as liver, kidney, lung, bone, prostate, breast, and pancreatic cancer, whether primary or metastatic. Most of these operations can be done as outpatient procedures or require an overnight stay in the hospital.

Impact of COVID-19 on the global interventional oncology market:

The recent global pandemic, COVID-19, has influenced the global interventional oncology market. As significant areas and governments adopted social distancing regulations and lockdowns, demand from the main end-users has dwindled. This effect is expected to be temporary, and no negative consequences are envisaged as the market gradually reopens. 

MARKET DRIVERS:

The growing cancer patient population is majorly driving the interventional oncology market growth.

As per the data published by International Agency for Research on Cancer (IARC), an estimated 17 million new cancer cases were recorded in 2018. According to the same source, approximately 27.5 million people are expected to be diagnosed with cancer by 2040, and cancer moralities are expected to be 16.3 million per year. The growing aging population, rising adoption of sedentary lifestyles by people and changes in the environment are some of the major factors behind the growing prevalence of cancer. In addition, the demand for effective cancer treatment procedures has grown with the growing population suffering from cancer, including interventional oncology procedures, resulting in market growth.

The rising demand for personalized medicine is anticipated to fuel the market’s growth rate.

The adoption of personalized medicine is growing among cancer patients as these treatments are believed to be more effective and have fewer side effects. Personalizing interventional oncology techniques such as tumor ablation and embolization has given promising results recently. This personalization is subject to the tumor size, location, and type. The demand for personalized cancer therapies has grown substantially in several countries due to improved patient care and increasing quality of life for cancer patients.

The growing adoption of minimally invasive surgeries is expected to favor the global interventional oncology market growth.

The popularity and adoption of minimally invasive surgeries have grown significantly in recent years due to the advantages of these surgeries, such as small incisions and quick recovery times compared to traditional surgeries. For instance, BTG International Ltd. joined hands with the Society of Interventional Oncology (SIO) to develop minimally invasive surgical therapies for cancer patients and to explore new interventional oncology treatment methods. As a result, the adoption of minimally invasive surgeries has risen in oncology procedures in recent years. Furthermore, the trend is expected to rise further in the coming years, resulting in market growth. As a result, minimally invasive surgeries in oncology, such as radiofrequency ablation and embolization, have been used considerably to treat cancer patients in recent years.

Furthermore, factors such as increasing healthcare expenditure, growing investments by governmental and non-governmental organizations to conduct R&D around interventional oncology, and an increasing number of partnerships and collaborations between the market players are projected to fuel the growth rate of the interventional oncology market in the coming years.

MARKET RESTRAINTS:

Despite the availability of a large target patient population, a shortage of oncologists and radiologists is predicted to affect the adoption of interventional oncology procedures in various countries worldwide. In addition, the lack of clinical evidence supporting the benefits of interventional oncology and implementing techniques to improve therapeutic outcomes and safety of interventional oncology treatments are seen as central challenges to the market's expansion throughout the forecast period.

REPORT COVERAGE:

This research report on the global interventional oncology market has been segmented and sub-segmented based on product, cancer type, end-user, and region.

Interventional Oncology Market – By Product:

• Embolization Devices
  • Radioembolic Agents
  • Non-Radio embolic Agents
    • Microspheres
    • Coated Beads
    • Microparticles
• Ablation Devices
  • Radiofrequency (R.F.) Ablation Devices
  • Microwave Ablation Devices
  • Cryoablation Devices
  • Other Ablation Devices
• Support Devices
  • Microcatheters
  • Guidewire

Based on product, the embolization devices segment had the major share of the interventional oncology market in 2022. The domination of the segment can be attributed to the growing usage of minimally invasive treatments for liver cancer patients, as these devices are mostly used in embolization procedures for liver cancer patients.

The ablation devices segment is expected to grow at a promising CAGR during the forecast period. Factors such as the growing adoption of these devices in cancer centers and hospitals for minimally invasive surgeries propel segmental growth.

The support devices segment had a moderate share of the worldwide market in 2022 and is expected to grow at a considerable CAGR during the forecast period. Support devices are essential in the execution of interventional oncology treatments, which is majorly contributing to the segment's growth.

Interventional Oncology Market – By Cancer Type:

• Liver Cancer
• Lung Cancer
• Bone Metastasis
• Kidney Cancer
• Breast Cancer
• Prostate Cancer
• Other Cancers

Based on cancer type, the liver cancer segment held the largest share of the global interventional oncology market in 2022. The domination of segment is expected to continue dominating the market throughout the forecast period as interventional oncology procedures such as transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) are the most preferred treatment procedures for liver cancer. The growing patient count suffering from liver cancer and rising demand for minimally invasive surgical procedures are expected to drive segmental growth. According to the American Cancer Society, an estimated 800,000 new liver cancers occur yearly. Liver cancer is the second most dangerous cancer among all types. The population suffering from liver cancer is gradually rising with each passing, resulting in the segment's growth rate.

The lung cancer segment accounted for the second-largest share of the global interventional oncology market in 2022 and is expected to grow at a notable CAGR during the forecast period. The growing lung cancer patient population is one of the key factors driving the segmental growth. According to the statistics published by the American Cancer Society, an estimated 238,340 new lung cancer cases are expected in the United States in 2023. In addition, factors such as the rising demand for minimally invasive surgical procedures such as microwave ablation, cryoablation, and brachytherapy to treat lung cancer and the increasing need for effective and accessible treatment options are promoting the growth of the lung cancer segment.

The breast cancer segment is another lucrative segment among the available and is predicted to register a healthy CAGR during the forecast period. The growing prevalence of breast cancer and the rising need for minimally invasive treatment options to treat breast cancer are majorly driving segmental growth. WHO says an estimated 685,000 people died of breast cancer in 2020.

Interventional Oncology Market – By End User:

• Hospitals
• Ambulatory Surgery Centers
• Research & Academic Institutes

Based on end-user, the hospital segment occupied the largest share of the global interventional oncology market in 2022. The segment’s domination is anticipated to continue during the forecast period as hospitals are equipped with the advanced medical infrastructure required to perform interventional oncology procedures. In addition, factors such as the presence of highly skilled professionals who have expertise in interventional oncology working at the hospitals, the growing number of cancer patients visiting hospitals for treatments, and strong referral networks are contributing to the segment's growth.

On the other hand, the ambulatory surgical centers segment is predicted to grow rapidly during the forecast period.

Interventional Oncology Market – By Region:

• North America
• Asia Pacific
• Europe
• Latin America
• The Middle East and Africa

The North American region held the leading share of the worldwide market in 2021. The domination of the North American region is expected to continue during the forecast period. Factors such as the growing cancer patient population in the North American region, the presence of sophisticated healthcare infrastructure, rapid adoption of technological developments in the healthcare system of North American countries, and the presence of key market participants are propelling the interventional oncology market growth in the North American region. In addition, the rising adoption of minimally invasive surgeries in cancer therapies is another noteworthy factor contributing to the growth of the North American market. The U.S. market captured the major share of the North American market in 2021, followed by Canada.

The APAC interventional oncology market is estimated to register the highest CAGR among all regions worldwide during the forecast period. The growing aging population is expected to fuel the market growth in APAC as cancer incidence is high among people aged. In addition, the growing number of favorable initiatives from the governments of APAC countries, a consistent number of developments in the healthcare infrastructure, and rising access to cancer care are expected to support the regional market growth. As a result, countries such as India and China are anticipated to hold the major share of the APAC market during the forecast period.

The European interventional oncology market occupied a substantial share of the global market in 2021 and is expected to grow considerably during the forecast period. The growing population suffering from cancer across the European region and the rising adoption of advanced medical technologies propel the European market growth. In addition, a well-advanced healthcare system in many European countries is another notable factor contributing to regional market growth.

The Latin American market is expected to hold a moderate share of the global market during the forecast period. The cancer patient population is growing gradually in Latin America, which is expected to create an increasing need for interventional oncology treatment procedures and boost regional market growth.

The MEA market is expected to register a steady CAGR in the coming years.

KEY MARKET PARTICIPANTS:

Angiodynamics, Inc., Baylis Medical Company, Inc., Becton, Dickinson and Company, Boston Scientific Corporation, Cook Medical, Healthtronics, Inc., Icecure Medical, Imbiotechnologies Ltd., Johnson & Johnson, Medtronic PLC, Medwaves, Inc., Merit Medical Systems, Inc., Profound Medical Corp., Sanarus Technologies, Inc., and Sirtex Medical are some of the prominent companies operating in the global interventional oncology market profiled in this report.

RECENT MARKET DEVELOPMENTS:

• Boston Scientific (U.S.) launched the TheraSphere Y-90 Glass Microspheres in 2021. TheraSphere is the most effective and potent HCC therapy that provides high-dose radiation safely and with the best possible results for patients.
• In December 2022, A research article titled Early Phase Trial of Intracystic Injection of Large Surface Area Microparticle Paclitaxel for Treatment of Mucinous Pancreatic Cysts in Endoscopy International Open was just published, according to NanOlogy LLC, a clinical-stage interventional oncology drug company.
• In December 2022, Delcath Systems (Nasdaq: DCTH) disclosed that the company had completed the previously disclosed $6.2 million private placement. Nearly 1.45 million shares of the interventional oncology company's common stock were issued and sold at $2.90 each. In addition, it sold 692,042 pre-funded warrants to buy common stock instead of common stock. Each warrant costs $2.89 in total.
• In January 2022, the following letter to shareholders was published today by IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM), developer of the ProSense® System, a minimally invasive cryoablation procedure that freezes malignancies to death.